Benjamin F. McGraw, III, PharmD
Doctor McGraw has been involved in senior leadership positions in multiple large and small pharmaceutical and biotechnology companies and investment management funds. He serves as executive chairman of Auration Biotech, Inc., a private biotechnology company focused on regenerative therapies for ear, nose and throat diseases, lead independent director for Aerie Pharmaceuticals, Inc., a public pharmaceutical company focused on new treatments for glaucoma and other diseases of the eye, executive chairman for Trefoil Therapeutics Inc., a private biopharmaceutical company focused on developing a regenerative approach to the treatment of corneal endothelial dystrophies and other diseases and chairman of TheraVida, Inc., a dermatology company developing a product discovered by Dr. McGraw and licensed to Dermavant Sciences, Ltd. Previously, Dr. McGraw was chairman, president, and CEO of Valentis, Inc., a public biotechnology company, corporate vice president, corporate development at Allergan, Inc., a public pharmaceutical company and VP, development at Marion Laboratories, Inc. and Marion Merrell Dow Inc. (now Sanofi US) public pharmaceutical companies. He previously served on the boards of other private pharmaceutical and biotechnology companies. His financial experience includes analyst and portfolio manager positions for hedge funds along with his role in advising investment decisions for venture funds. Doctor McGraw received his B.S. and his Doctor of Pharmacy from the University of Tennessee Health Science Center where he also completed a clinical practice residency. He has completed executive training programs at Harvard, Wharton, Kellogg and Columbia business schools.